Latham & Watkins Advises the Underwriters in Design Therapeutics’ Initial Public Offering

Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of US$20 per share.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Bay Area partner Brian Cuneo, Orange County partner Drew Capurro, and San Diego partner Matt Bush, with Orange County associate Mekbeb Hagos. Advice as also provided on benefits and compensation matters by Bay Area partner James Metz, with Bay Area associate Nathaniel Hsieh; on intellectual property matters by Bay Area partner Chris Hazuka, with San Diego associate Robert Yeh and New York associate David Suh; on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associate Julie Choi Shin; and on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu.